Basic | |
---|---|
Market Cap | $233.12B |
Price | $289.61 |
52 Week Range | 233.12-340.88 |
Beta | 0.14 |
Margins | |
Gross Profit Margin | 73.61% |
Operating Profit Margin | 29.72% |
Net Profit Margin | 17.79% |
Valuation (TTM) | |
P/E Ratio | 20.45 |
Price to Sales Ratio | 3.64 |
Price to Book Ratio | 7.50 |
PEG Ratio | 0.20 |
Drug Manufacturers - General
Healthcare
103,605
2009-02-13T00:00:00.000Z
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
41 61 688 11 11
Grenzacherstrasse 124, Basel, 4058, CH